Everything below concerns analytical characterisation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-13. Numbers and descriptions here follow the published literature rather than marketing material.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
== Economy == According to historian Quinn Slobodian, Ciskei, on the suggestion of a group of economists led by South African Leon Louw—called the "supply siders of Ciskei" by the Financial Times --, was operated as a de facto export processing zone of South Africa. Its economy was centered around the textile industry, with a majority female workforce, and was reliant on Taiwanese and Hong Kong investors, generous investor incentives by the South African government (including paying the wages of their employees, subsidizing 80% of their factories' rents, and not charging corporate tax), and repression of the labour movement.
== Spy&Go affinity purification == Mutation of the catalytic glutamic acid residue (E77) in SpyCatcher to alanine stops isopeptide bond formation but does not prevent the initial non-covalent SpyTag/SpyCatcher association. This non-covalent SpyTag/SpyCatcher interaction has been utilized in the affinity purification of SpyTag-fused recombinant proteins. In this purification strategy, termed Spy&Go, resin-immobilized SpyCatcher is used to harvest SpyTag-fused proteins from cell culture supernatants or cell lysates. Non-specifically bound proteins are removed by washing the resin with a neutral buffer and the target protein eluted at neutral pH using high imidazole concentration. The Spy&Go affinity resin is based on SpyCatcher2.1 E77A S49C variant termed SpyDock. SpyDock can be expressed in E. coli as soluble protein, purified using Ni-NTA and anion-exchange resins and immobilized to iodoacetyl-activated agarose through the unpaired cysteine introduced by the S49C substitution. In neutral buffers with physiological salt concentration SpyDock binds to SpyTag- and SpyTag002-fused proteins with affinity in the high nanomolar range (Kd = 750 ± 50 nM for SpyTag, Kd = 73 ± 13 nM for SpyTag002). Affinity to SpyTag003 has not been reported, but requires harsher conditions to ensure full dissociation suggesting it binds tighter. SpyDock-bound proteins are eluted by incubating the resin with 2.5 M imidazole in neutral buffer. The SpyDock resin can be regenerated several times using consecutive washes with 4 M imidazole, 6 M guanidinium hydrochloride and 0.1 M NaOH.
It also offered a longer range of transmission between the sensor and receiver, as well as a color LCD. The G4 Platinum was approved by the FDA for use in patients ages 2–17 in February 2014. Dexcom received FDA approval in January 2015 for the G4 Platinum with Share, which enabled the sharing of CGM data with up to five other people using the "Share" and "Follow" smartphone apps. The Dexcom G5 was approved in August 2015 by the FDA for use as a standalone device, the G5 has Bluetooth integrated into its transmitter, enabling it to send data to a mobile device. This allows for use of the device without the standalone receiver. The Dexcom G5 received a CE mark in September 2015. Dexcom went public in 2005 and is listed on the Nasdaq Global Select Market stock exchange under the ticker symbol DXCM. On April 20, 2020, Dexcom became a component of the Nasdaq-100, replacing American Airlines Group in the index. The Dexcom G7 was approved in December 2022 by the FDA for use as a standalone device. The Dexcom G7 15-Day is the most accurate currently approved CGM in the U.S.
The most famous of these took place during the Battle of Smolensk under the command of Lev Dovator, whose 3rd Cavalry Corps consisted of the 50th and 53rd Cavalry divisions from the Kuban and Terek Cossacks mobilised from the Northern Caucasus. The raid in ten days covered 300 km and destroyed the hinterlands of the 9th German Army before successfully breaking out. Whilst units under the command of General Pavel Belov, the 2nd Cavalry Corps of Don, Kuban and Stavropol Cossacks spearheaded the counter-attack onto the right flank of the 6th German Army, delaying its advance towards Moscow. The high professionalism that the Cossacks under Dovator and Belov (both generals would later be granted the title Hero of the Soviet Union and their units raised to a Guards (elite) status) ensured that many new units would be formed. The Germans during the whole war only managed to form two Cossack Corps, while the Red Army in 1942 alone had 17. Many of the newly formed units were filled with ethnically Cossack volunteers. The Kuban Cossacks were allocated to the 10th, 12th and 13th Corps. However, the most famous Kuban Cossack unit was the 17th Cossack Corps under the command of general Nikolay Kirichenko. During one particular attack, Cossacks killed up to 1,800 enemy soldiers and officers, took 300 prisoners, and seized 18 artillery pieces and 25 mortars. The 5th and 9th Romanian Cavalry divisions fled in panic, and the 198th German Infantry division hastily departed with large losses to the left bank of the river Ei.
== Clinical significance == Reactive electrophiles produced by oxidative metabolism have been linked to a number of degenerative diseases including Parkinson's disease, Alzheimer's disease, cataract formation, and atherosclerosis hence reduced expression of the GSTA4 enzyme may have pathophysiological consequences. The expression of this gene is decreased drastically among burn and trauma victims.
Sources: en.wikipedia.org
The corresponding monotherapy dosage of bicalutamide in the treatment of prostate cancer is 150 mg/day. Flutamide has also been employed as an antiandrogen in transgender women, with at least two treatment centers at one point reporting its frequent use. In the studies of nilutamide for transgender hormone therapy, the medication, given alone and not in combination with estrogen, induced observable signs of feminization in young transgender women (ages 19–33 years) within 8 weeks. These changes included breast development, decreased male-pattern hair, decreased spontaneous erections and sex drive, and positive psychological and emotional changes. Signs of breast development, such as increased nipple sensitivity, were, along with decreased male-pattern hair, the earliest indications of feminization, and occurred in all subjects within 6 weeks. Nilutamide by itself more than doubled luteinizing hormone (LH) and testosterone levels and tripled estradiol levels. The addition of 100 μg/day oral ethinylestradiol to nilutamide therapy after 8 weeks abolished the increase in LH, testosterone, and estradiol levels and dramatically suppressed testosterone levels, into the female or castrate range. On the basis of these results, both nilutamide alone, and particularly the combination of nilutamide and estrogen, were regarded as effective for producing antiandrogenic effects and feminization in transgender women.
=== Aortic stenosis === Aortic stenosis is typically the result of aging, occurring in 12.4% of the population over 75 years of age, and represents the most common cause of outflow obstruction in the left ventricle. Bicuspid aortic valves are found in up to 1% of the population, making it one of the most common cardiac abnormalities.
== Medical uses == Histidine’s role in skin health has attracted research interest because the amino acid is a precursor to filaggrin, a structural protein that helps maintain the integrity of the skin’s outer barrier. Filaggrin is rich in histidine and, when broken down, contributes to the natural moisturizing factor that helps retain moisture and supports barrier function. Clinical studies suggest that oral L-histidine supplementation can increase filaggrin processing and improve skin barrier function, with corresponding reductions in the severity of atopic dermatitis (eczema) compared with placebo, potentially offering a safe, nonsteroidal adjunct to traditional therapies. In the skincare industry, biotechnology companies such as Codex Labs— a dermatology and firm developing skin-gut-brain-biome solutions for conditions including eczema — have incorporated histidine-containing formulations into products and supplements aimed at strengthening the skin barrier and supporting sensitive skin, reflecting growing interest in histidine’s functional importance beyond its canonical metabolic roles.
Investigational ASO approaches have also been reported for rare genetic epilepsies, including KCNT1-associated developmental and epileptic encephalopathy, where knockdown of KCNT1 has been studied in preclinical human neuronal models and in two treated children, and prenatal targeting
Sources: en.wikipedia.org
=== Mass Spectrometry === Mass spectrometry confirms molecular mass and provides insights into cage assembly processes. High-resolution mass spectrometry precisely determines the molecular weight of completed cages and can identify reaction intermediates during synthesis. The technique is particularly valuable for large cage structures where multiple charge states may be observed. Tandem mass spectrometry reveals fragmentation patterns that confirm structural assignments and can provide information about the strength of various bonds within the cage framework. Modern ionization techniques enable the study of host-guest complexes, offering insights into molecular recognition properties.
The Rosenmund reduction of 3-(trifluoromethylthio)benzoyl chloride [51748-28-8] (1) gave 3-((trifluoromethyl)thio)benzaldehyde [51748-27-7] (2). Henry reaction with nitroethane led to 1-(2-nitroprop-1-en-1-yl)-3-[(trifluoromethyl)sulfanyl]benzene [176242-84-5] (3). With the aid of iron catalyst in concentrated HCl acid there occurred FGI into 1-(3'-trifluoromethylthiophenyl)-2-propanone, CID:21325269 (4'). Reductive amination with ethylamine and formic acid as the reductant completed the synthesis of tiflorex (5).
=== High population densities === Since sea ice pockets are confined and highly-concentrated ecosystems, they are able to house several orders of magnitude greater population densities of bacteria and protists than are found in the open ocean (up to thousands of individuals per liter for protists). This high abundance of organisms can pose challenges, as different bacteria and protists will compete for resources. A high density of microorganisms can result in the accumulation of metabolic byproducts, such as oxygen, dissolved organic matter, ammonia, and dimethylsulfoniopropionate (DMSP). Some organisms can gain a selective advantage within brine pockets as the high population density can result in increased rates of horizontal gene transfer because organisms are in close proximity. Horizontal gene transfer can allow certain organisms to obtain genes from bacteria that may be advantageous in a light-limited, extremely cold environment.
Consistent with the move away from questions of blame to questions of culture and ideology, American historians have also begun exploring the intersection between domestic U.S. political developments and the early years of Cold War outbreak. One such example is Thomas Borstelmann's 2003 work "The Cold War and the Color Line", which defines domestic racial discrimination after 1945 as a foreign as well as a domestic issue: America’s closest allies against the Soviet Union were colonial powers who had interests that needed to be balanced against those of the emerging 'Third World' in a diverse multiracial, anti-Communist alliance. Domestically, at the same time, U.S. racial reform was essential to preserve the national consensus needed to sustain the Cold War struggle.
Carole Ann Bewley is an American chemist. She is a senior investigator and Chief of the Laboratory of Bioorganic Chemistry at the United States National Institute of Diabetes and Digestive and Kidney Diseases. Bewley researches secondary metabolites and basic principles involved in protein-carbohydrate interactions and how these can be exploited to engineer therapeutics.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.